Navicixizumab Phase 1b data presented in Journal of Clinical Oncology
2022-04-22 · Mereo BioPharma · original mereobiopharma.com ↗
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology. View publication Privacy Notice Cookie Notice Medical Inquiries LinkedIn NASDAQ: MREO Share Price: Mereo BioPharma Group plc ©2026 Last Updated: October 2025 Welcome This page is intended for Healthcare Professionals only. Please confirm that you are a Healthcare Professional. Yes No You are now leaving the Mereo BioPharma website. This link is provided as a courtesy. Mereo BioPharma is not responsible for the content or privacy practices of external websites. We recommend reviewing the privacy policy of any site you choose to visit. Click 'Cancel' to stay on the Mereo BioPharma website, or 'Continue' to proceed to the external site. Continue Cancel
The release as fetched from its publisher. mereobiopharma.com ↗